81 related articles for article (PubMed ID: 3198216)
41. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy.
Ali-Osman F; Berger MS; Rairkar A; Stein DE
J Cell Biochem; 1994 Jan; 54(1):11-9. PubMed ID: 8126081
[TBL] [Abstract][Full Text] [Related]
42. Cisplatin-DNA adduct determination in the hepatic albumin gene as compared to whole genomic DNA.
Zhang Z; Poirier MC
Chem Res Toxicol; 1997 Sep; 10(9):971-7. PubMed ID: 9305578
[TBL] [Abstract][Full Text] [Related]
43. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Reed E; Gupta-Burt S; Litterst CL; Poirier MC
Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
[TBL] [Abstract][Full Text] [Related]
44. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion?
Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; van der Velde-Visser SD; Berends F; Baan RA
Carcinogenesis; 1995 Oct; 16(10):2447-53. PubMed ID: 7586150
[TBL] [Abstract][Full Text] [Related]
45. Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.
Terheggen PM; Floot BG; Lempers EL; van Tellingen O; Begg AC; den Engelse L
Cancer Chemother Pharmacol; 1991; 28(3):185-91. PubMed ID: 1855275
[TBL] [Abstract][Full Text] [Related]
46. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
Hospers GA; de Vries EG; Mulder NH
Br J Cancer; 1990 Jan; 61(1):79-82. PubMed ID: 2153398
[TBL] [Abstract][Full Text] [Related]
47. Influence of the degree of DNA modification on the immunochemical determination of cisplatin-DNA adduct levels.
Fichtinger-Schepman AM; Baan RA; Berends F
Carcinogenesis; 1989 Dec; 10(12):2367-9. PubMed ID: 2591026
[TBL] [Abstract][Full Text] [Related]
48. Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.
Welters MJ; Maliepaard M; Jacobs-Bergmans AJ; Baan RA; Schellens JH; Ma J; van der Vijgh WJ; Braakhuis BJ; Fichtinger-Schepman AM
Carcinogenesis; 1997 Sep; 18(9):1767-74. PubMed ID: 9328174
[TBL] [Abstract][Full Text] [Related]
49. Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients.
Boffetta P; Fichtinger-Schepman AM; Weiderpass E; van Dijk-Knijnenburg HC; Stoter G; van Oosterom AT; Keizer HJ; Fosså SD; Kaldor J; Roy P
Anticancer Drugs; 1998 Feb; 9(2):125-9. PubMed ID: 9510497
[TBL] [Abstract][Full Text] [Related]
50. A novel technique to assay adducts of DNA induced by anticancer agent cis-diamminedichloroplatinum(II).
Sharma M; Jain R; Isac TV
Bioconjug Chem; 1991; 2(6):403-6. PubMed ID: 1805936
[TBL] [Abstract][Full Text] [Related]
51. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.
Poirier MC; Reed E; Shamkhani H; Tarone RE; Gupta-Burt S
Environ Health Perspect; 1993 Mar; 99():149-54. PubMed ID: 8319613
[TBL] [Abstract][Full Text] [Related]
52. Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models.
Poirier MC; Reed E; Zwelling LA; Ozols RF; Litterst CL; Yuspa SH
Environ Health Perspect; 1985 Oct; 62():89-94. PubMed ID: 4085451
[TBL] [Abstract][Full Text] [Related]
53. Conversion of DNA adducts of antitumour cis-diamminedichloroplatinum(II). Immunochemical analysis.
Vrána O; Kiseleva VI; Poverenny AM; Brabec V
Eur J Pharmacol; 1992 May; 226(1):5-13. PubMed ID: 1397055
[TBL] [Abstract][Full Text] [Related]
54. Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA.
Olivero OA; Chang PK; Lopez-Larraza DM; Semino-Mora MC; Poirier MC
Mutat Res; 1997 Jun; 391(1-2):79-86. PubMed ID: 9219551
[TBL] [Abstract][Full Text] [Related]
55. DNA adducts induced by platinum drug chemotherapeutic agents in human tissues.
Poirier MC; Shamkhani H; Reed E; Tarone RE; Gupta-Burt S
Prog Clin Biol Res; 1992; 374():197-212. PubMed ID: 1620704
[No Abstract] [Full Text] [Related]
56. Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation.
Fichtinger-Schepman AM; Lohman PH; Reedijk J
Nucleic Acids Res; 1982 Sep; 10(17):5345-56. PubMed ID: 6216456
[TBL] [Abstract][Full Text] [Related]
57. The isolation and identification of cis-diamminedichloroplatinum (ii)-DNA adducts by anion-exchange HPLC and inductively coupled plasma mass-spectrometry.
Morrison J; Bissett D; Stephens I; McKay K; Brown R; Graham M; Fichtingerschepman A; Kerr D
Int J Oncol; 1993 Jan; 2(1):33-7. PubMed ID: 21573512
[TBL] [Abstract][Full Text] [Related]
58. Differences in in vivo and in vitro sequence-specific sites of cisplatin-DNA adduct formation and detection of a dose-response relationship.
Bubley GJ; Teicher BA; Ogata GK; Sandoval LS; Kusumoto T
Biochem Pharmacol; 1994 Jul; 48(1):145-53. PubMed ID: 8043016
[TBL] [Abstract][Full Text] [Related]
59. Preliminary characterization of the adducts formed between the antitumor compounds cis-Pt(NH3)2Cl2 and DNA.
Johnson NP
Biochem Biophys Res Commun; 1982 Feb; 104(4):1394-400. PubMed ID: 7041911
[No Abstract] [Full Text] [Related]
60. Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA.
Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; Dijt FJ; van der Velde-Visser SD; Berends F; Baan RA
J Inorg Biochem; 1995 May; 58(3):177-91. PubMed ID: 7782787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
